Brigham and Women's Hospital
The Industrial Participant Program, part of the Wyss Diagnostics Accelerator, provides a hub for collaboration and guidance to move promising tech forward.
Bio-Techne, Thermo Fisher Scientific to Further Develop, Commercialize Kidney Transplant Rejection Assay
The exosome-based, liquid biopsy assay discriminates between T-cell mediated rejection and antibody mediated rejection to help improve patient outcomes.
Brigham and Women's Hospital Partners With CureDuchenne on Newborn Screening Program
Brigham and Women's will offer at no cost a blood test that detects elevated levels of an enzyme associated with Duchenne muscular dystrophy.
Wyss Institute, Brigham and Women's Hospital Launch Diagnostic Technology Accelerator
Through the accelerator, Brigham and Women's investigators will identify diagnostic challenges that will be matched with technologies created by Wyss engineers.
AI-Based Pathology Method Developed to Potentially Uncover Cancers of Unknown Primary Origin
Premium
In a paper published in Nature, Brigham and Women's researchers describe a novel computational pathology method to improve diagnosis and treatment of metastatic cancers.